Yeju Healthcare (06929) announced interim results. Profit attributable to shareholders of US$21.569 million increased 9.0% year-on-year, with an interim dividend of 8 Hong Kong cents

According to the Zhitong Finance App, Yeju Healthcare (06929) announced interim results for the six months ended June 30, 2026. The group's revenue was US$98.707 million, up 18.1% year on year; profit attributable to shareholders was US$21.569 million, up 9.0% year on year; basic profit per share was 2.62 US cents; and an interim dividend of HK8 cents.

Through direct sales teams and distributors, Yeju Medical has established an extensive sales network covering more than 70 countries and regions around the world. In the first half of 2026, the Group continued to actively expand its business footprint. Among them, the Group set up its own sales teams in Belgium, the Netherlands and Luxembourg, and successfully transformed these markets into direct sales markets. This expansion brought the total number of direct sales teams to 15. Other direct sales markets include Hong Kong, Macau, Taiwan, Japan, Indonesia, Malaysia, Singapore, Germany, France, Switzerland, Spain, and Monaco. As of June 30, 2026, the Group had 319 sales and marketing personnel (December 31, 2025:296) and 335 dealers (December 31, 2025:411). In the six months ended June 30, 2026, direct sales and dealer sales were approximately US$59.5 million and US$39.2 million respectively, accounting for 60.3% and 39.7% of the Group's total revenue, respectively.

To deepen interaction with healthcare professionals and strengthen the brand influence of Yeju Healthcare, the Group participated in 72 seminars, workshops and industry conferences around the world, including TCTAP, EuroPCR and MLCTO. For example, a clinical report on eucalimus was published at EuroPCR in May 2026. The study evaluated the 3-year clinical results of the ultra-thin stent drug-eluting stent in complex coronary artery disease and proved that the drug-eluting stent has long-lasting long-term safety and efficacy as a reliable treatment for complex PCI. In addition, the Group held 3 doctors' exchange events in Hong Kong and Malaysia to promote knowledge exchange and strengthen relationships with healthcare professionals.